Yasuhiro Hiyoshi
Overview
Explore the profile of Yasuhiro Hiyoshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kusuhara S, Igawa S, Ichinoe M, Nagashio R, Kuchitsu Y, Hiyoshi Y, et al.
Thorac Cancer
. 2021 Apr;
12(10):1570-1578.
PMID: 33793071
Background: Galectin-3 (GAL3), a protein encoded by the LGALS3 gene, plays diverse roles in cancer initiation, progression, and drug resistance. Accordingly, high GAL3 expression in tumor cells is associated with...
2.
Fukui T, Hosotani S, Soda I, Ozawa T, Kusuhara S, Kakegawa M, et al.
Thorac Cancer
. 2020 Feb;
11(4):1005-1014.
PMID: 32057187
Background: The standard treatment for patients with unresectable locally advanced (LA) non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was...
3.
Hiyoshi Y, Sato Y, Ichinoe M, Nagashio R, Hagiuda D, Kobayashi M, et al.
Thorac Cancer
. 2019 Oct;
10(11):2142-2151.
PMID: 31583841
Background: Mitochondrial dysfunction contributes to many types of human disorders and cancer progression. Inner membrane mitochondrial protein (IMMT) plays an important role in the maintenance of mitochondrial structure and function....
4.
Igawa S, Ono T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, et al.
Cancer Manag Res
. 2019 Jun;
11:4883-4892.
PMID: 31213907
A T790M of the epidermal growth factor receptor (EGFR) is the most frequently encountered mutation conferring acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)....
5.
Shirasawa M, Fukui T, Kusuhara S, Harada S, Nishinarita N, Hiyoshi Y, et al.
PLoS One
. 2019 Apr;
14(4):e0214599.
PMID: 31002722
Purpose: Oligometastasis is a state in which cancer patients have a limited number of metastatic tumors; patients with oligometastases survive longer than those with polymetastases. Extensive disease (ED)-small cell lung...
6.
Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, et al.
Thorac Cancer
. 2019 Mar;
10(4):880-889.
PMID: 30821083
Background: Osimertinib is recommended for non-small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients....
7.
Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Nakahara Y, Nishinarita N, et al.
BMC Cancer
. 2019 Feb;
19(1):163.
PMID: 30808322
Background: Small cell lung cancer (SCLC) is characterized by a high propensity for metastases and a poor prognosis irrespective of high sensitivity for initial chemotherapy. Although interstitial pneumonia (IP) is...
8.
Fukui T, Ishihara M, Kasajima M, Hiyoshi Y, Nakahara Y, Otani S, et al.
Thorac Cancer
. 2019 Jan;
10(3):501-507.
PMID: 30648806
Background: Treatment strategies for patients with non-small cell lung cancer (NSCLC) depend on various factors including physical condition, complications, tumor histology, and molecular profiling. Even if initial chemotherapy is efficacious,...
9.
Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Ishihara M, Kasajima M, et al.
Cancer Manag Res
. 2018 Dec;
10:6039-6047.
PMID: 30538553
Background: Small cell lung cancer (SCLC) is typically categorized according to disease extent as limited or extensive, and utility of the 8th TNM classification, recommended for lung cancer staging, which...
10.
Sone H, Igawa S, Kasajima M, Ishihara M, Hiyoshi Y, Hosotani S, et al.
Thorac Cancer
. 2018 Aug;
9(10):1279-1284.
PMID: 30126051
Background: Previous studies have shown amrubicin (AMR) to be an effective second-line treatment option for small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC...